Revive Therapeutics Ltd.
5 Director Court, Suite 105
Vaughan
Ontario
L4L 4S5
Canada
Tel: 905-605-5535
Fax: 905-248-3355
Website: http://www.revivethera.com/
134 articles with Revive Therapeutics Ltd.
-
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
3/20/2023
Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19.
-
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
3/8/2023
Revive Therapeutics Ltd. announces today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) to obtain agreement on the proposed protocol endpoints for the Company’s Phase 3 Study (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.
-
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
2/6/2023
PharmAla Biotech Holdings Inc. is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDMA to Revive Therapeutics .
-
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
2/3/2023
Revive Therapeutics Ltd. is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine using PharmaTher’s novel microneedle patch delivery technology.
-
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
1/19/2023
Revive Therapeutics Ltd. announces today that it has submitted the updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include the rationale for the proposed primary and efficacy endpoints for the amended protocol in the treatment of COVID-19 and supporting new information and independent published studies, including the most recent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction.”
-
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
1/12/2023
Revive Therapeutics Ltd. announces it will submit an updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include additional supporting information and the data from the independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto.
-
Revive Therapeutics Ltd. Closes $4.3 Million Offering
1/12/2023
REVIVE THERAPEUTICS LTD. is pleased to announce that it has completed the closing of its previously announced private placement by issuing a total of 28,676,064 units, at a price of $0.15 per Unit, for gross proceeds of $4,301,409.
-
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
1/9/2023
Revive Therapeutics Ltd. announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.
-
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
1/5/2023
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R) announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.
-
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
12/22/2022
Revive Therapeutics Ltd. announced that it has submitted the Type C meeting request package to the U.S. Food & Drug Administration to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Revive Therapeutics Ltd. Expands Life Offering to Quebec
12/15/2022
REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“ Revive ” or the “ Company ”) announces that it is expanding its previously announced private placement (see November 30, 2022 press release) to investors resident in the Province of Quebec.
-
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
11/30/2022
REVIVE THERAPEUTICS LTD. is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per Unit.
-
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
11/24/2022
Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
11/22/2022
Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a Type C meeting would be recommended, which the Company will request, to discuss the overall development plan and the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
10/14/2022
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) announced today that it has finalized an amended protocol to the U.S. Food & Drug Administration (“FDA”) for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.
-
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
-
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
9/16/2022
Revive Therapeutics Ltd. is pleased to provide an update on the Company’s Phase I/II clinical study of oral psilocybin in the treatment of methamphetamine use disorder and the development of its proprietary oral psilocybin thin film strip product.
-
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
9/14/2022
Revive Therapeutics Ltd. announced that it has filed an amended protocol to the U.S. Food & Drug Administration for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.